EP0697870A1 - Modulateur du recepteur btp du complexe gaba a?/vanne a chlorure servant a prolonger le courant membranaire induit par gaba - Google Patents

Modulateur du recepteur btp du complexe gaba a?/vanne a chlorure servant a prolonger le courant membranaire induit par gaba

Info

Publication number
EP0697870A1
EP0697870A1 EP94915541A EP94915541A EP0697870A1 EP 0697870 A1 EP0697870 A1 EP 0697870A1 EP 94915541 A EP94915541 A EP 94915541A EP 94915541 A EP94915541 A EP 94915541A EP 0697870 A1 EP0697870 A1 EP 0697870A1
Authority
EP
European Patent Office
Prior art keywords
gab
chloride channel
gaba
btp
die
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94915541A
Other languages
German (de)
English (en)
Inventor
Christopher D. SmithKline Beecham Pharm. BENHAM
Helen Jane SmithKline Beecham Pharm. MEADOWS
David Richard SmithKline Beecham Pharm. THOMAS
Martyn Derek SmithKline Beecham Pharm. WOOD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0697870A1 publication Critical patent/EP0697870A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the therapeutic use of compounds found to 5 modulate a novel allostenc site of the GAB A A /Chloride channel complex.
  • Benzodiazepines exhibit a wide range of pharmacological actions, including anxiolytic activity which are mediated by specific high affinity receptor sites in the central nervous system.
  • the benzodiazepine receptor is one constituent of a supra molecular complex which also contains separate, but allosterically coupled, recognition sites for 0 ⁇ -aminobutyric acid (GABA) and barbiturates.
  • GABA 0 ⁇ -aminobutyric acid
  • barbiturates The oligomeric units of the
  • GAB A A /Chloride complex form a drug and transmitter controlled chloride channel. In the presence of GABA this channel is opened causing a GAB A-induced chloride ion current.
  • GAB A-induced chloride ion current It is known that [35S]-t-butyl-bicyclophosphorothionate (TBPS) binds with high affinity to the GAB A A complex when the chloride channel is in the closed state but with 5 low affinity when in the open state.
  • Anxiolytics such as benzodiazepines and barbiturates allosterically inhibit TBPS binding and it is thought that they do this by promoting GAB A induced chloride conductance, Le. shifting the channel to the open state.
  • PCT/GB92/02046 and PCT/GB92/02298 disclose certain ⁇ -carboline and tetrahydro- benzothienopyridine derivatives having CNS activity, such as anxiolytic, anti-depressant or anticonvulsant activity or activity useful in the treatment of sleep disorders.
  • CNS activity such as anxiolytic, anti-depressant or anticonvulsant activity or activity useful in the treatment of sleep disorders.
  • the latter five applications also disclose that such compounds inhibit TBPS binding implying that 5 they modulate the GAB A A /Chloride channel in similar manner to conventional anxiolytics such as the benzodiazepines and barbiturates.
  • the present invention provides the use of a BTP receptor modulator of the GAB A A /Chloride channel complex in the manufacture of a medicament for prolonging the duration of the GAB A-induced membrane current
  • the present invention provides the use of a BTP receptor modulator of the GAB A A /Chloride channel complex excluding compounds disclosed in the above-noted patent applications in the manufacture of a medicament for the treatment and/or prophylaxis of CNS disorders such as anxiety, sleep disorders, depression or disorders treatable with anti-convulsant agents, such as epilepsy, without the side effects normally associated with the benzodiazepine or barbiturate GAB A A /Chloride channel modulators.
  • the present invention provides the use of a compound which prolongs the duration of the GAB A-induced membrane current excluding compounds disclosed in the above-noted patent applications in the manufacture of a medicament for the treatment and/or prophylaxis of CNS disorders such as anxiety, sleep disorders, depression or disorders treatable with anti-convulsant agents, such as epilepsy, without th side effects normally associated with the benzodiazepine or barbiturate GAB A A /Chloride channel modulators.
  • BTP receptor modulators of the GAB A A /Chloride channe complex which prolong the duration of the GABA-induced membrane current include :
  • a BTP receptor modulator will be administered as a pharmaceutical composition comprising the active medicament, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted fo oral or parenteral administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, or injectable or infusable solutions or suspensions. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle
  • the compound depending on the vehicle and concentration used, can be either suspended dissolved in the vehicle.
  • the compound can be dissolved for injecti and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents a dissolved in the vehicle.
  • the composition can be frozen after filli into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instea of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the composition may contain from 0.1 % to 99% by weight, preferably from 10 to
  • suitable unit doses may be 0.05 to 1000 mg, for anxiety more suitably 0.05 to 20.0 mg, for example 0.2 to 10 mg; and such u doses may be administered more than once a day, for example two or three a day, so that t total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may exten for a number of weeks or months.
  • the present invention provides a method of screening a compound for use in the treatment and/or prophylaxis of CNS disorders such as anxiety, sleep disorders, depression or disorders treatable with anti-convulsant agents, such as epilepsy, without the side effects normally associated with the benzodiazepine or barbitur GAB A A /Chloride channel modulators which method comprises measuring the ability of a compound to prolong die duration of the GAB A-induced membrane current.
  • Bovine adrenomedullary chromaffin cells were isolated and cultured by die method of Peters et al. (1989) and used for electrophysiological recordings 1-2 days after plating.
  • cells were continually perfused with a solution containing (mM): NaCl 140, KC12.5, CaCl2 1.5, MgCl2 1.2, HEPES 10 and glucose 10 (pH adjusted to 7.4 with NaOH).
  • the perfiision system operates by gravity an uses large bore tubing placed directly in line with the cell. This system allows rapid solution exchange at the cell surface with exchange possible within approximately 100ms.
  • the patch pipette solution contained in mM: CsCl 140, MgCl24, HEPES 10, EGTA 10 and NaATP 2, and was adjusted to pH 7.2 with CsOH.
  • cells were held at a membrane potential of around -80mV in the 'whole-cell configuration' of the patch clamp technique (Hamill et al. 1981).
  • Currents were evoked in response to a pulse of GABA or GABA plus the test compound which is applied through the perfiision system for approximately 7 seconds.
  • Current responses were evoked at approximately one minute intervals and were stored on die computer for latter analysis.
  • the figure shows currents evoked from a cell in response to GABA (lOpM) alone and in the presence of modulating drugs.
  • Compound A, pentobarbitone and diazepam all potentiated die GAB A-induced current with Compound A having the additional effect of dramatically slowing the decay rate of the current on washout of GABA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation thérapeutique de composés modulant un nouveau site allostérique du complexe GABAA/vanne à chlorure.
EP94915541A 1993-05-05 1994-04-26 Modulateur du recepteur btp du complexe gaba a?/vanne a chlorure servant a prolonger le courant membranaire induit par gaba Withdrawn EP0697870A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939309179A GB9309179D0 (en) 1993-05-05 1993-05-05 New use
GB9309179 1993-05-05
PCT/EP1994/001299 WO1994025027A1 (fr) 1993-05-05 1994-04-26 Modulateur du recepteur btp du complexe gabaa/vanne a chlorure servant a prolonger le courant membranaire induit par gaba

Publications (1)

Publication Number Publication Date
EP0697870A1 true EP0697870A1 (fr) 1996-02-28

Family

ID=10734911

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94915541A Withdrawn EP0697870A1 (fr) 1993-05-05 1994-04-26 Modulateur du recepteur btp du complexe gaba a?/vanne a chlorure servant a prolonger le courant membranaire induit par gaba

Country Status (4)

Country Link
EP (1) EP0697870A1 (fr)
JP (1) JPH08509717A (fr)
GB (1) GB9309179D0 (fr)
WO (1) WO1994025027A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912091B1 (fr) * 1996-05-24 2007-12-19 Smithkline Beecham Corporation Utilisation d'inhibiteurs de l'absorption de gaba comme agents antitussifs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8600651D0 (en) * 1986-01-11 1986-02-19 Beecham Group Plc Compounds
GB8801491D0 (en) * 1988-01-22 1988-02-24 Beecham Group Plc Novel compounds
GB8828806D0 (en) * 1988-12-09 1989-01-18 Beecham Group Plc Novel compounds
GB9010296D0 (en) * 1990-05-08 1990-06-27 Beecham Group Plc Novel compounds
GB9117459D0 (en) * 1991-08-13 1991-09-25 Smithkline Beecham Plc Novel compounds
JPH07500831A (ja) * 1991-11-07 1995-01-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｃｎｓ活性テトラヒドロベンゾチエノピリジン
GB9127188D0 (en) * 1991-12-21 1992-02-19 Smithkline Beecham Plc Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9425027A1 *

Also Published As

Publication number Publication date
JPH08509717A (ja) 1996-10-15
WO1994025027A1 (fr) 1994-11-10
GB9309179D0 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
Freedman et al. Identification and characterization of voltage-sensitive calcium channels in neuronal clonal cell lines
RU2225203C2 (ru) Фармацевтическая композиция, включающая положительный модулятор агониста никотинового рецептора и агонист никотинового рецептора, способ лечения
Delpy et al. NKCC1 cotransporter inactivation underlies embryonic development of chloride‐mediated inhibition in mouse spinal motoneuron
Bevan et al. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin
Konradi et al. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia
JP5390184B2 (ja) 貧血の改良された治療方法
DE60214846T2 (de) Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
US20040092528A1 (en) Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property
Ling et al. Cyclosporin A inhibits apical secretory K+ channels in rabbit cortical collecting tubule principal cells
Green et al. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients
CA2132509A1 (fr) Traitement of anxiety with the aid of (s)-(-)-.alpha.-ethyl-2-oxo-1-pyrrolidineacetamide
Gregory et al. Evidence that Ca2+-release-activated Ca2+ channels in rat hepatocytes are required for the maintenance of hormone-induced Ca2+ oscillations
Smitherman et al. Inhibition of glial Na+ and K+ currents by tamoxifen
EP0697870A1 (fr) Modulateur du recepteur btp du complexe gaba a?/vanne a chlorure servant a prolonger le courant membranaire induit par gaba
EP1658062B1 (fr) Derives d'alpha-aminoamide utilisables comme agents anti-inflammatoires
DE69910425T2 (de) Neue therapeutische verwendung von nicergoline
Brown et al. Block of human voltage‐sensitive Na+ currents in differentiated SH‐SY5Y cells by lifarizine
Qian et al. Zinc enhances ionic currents induced in skate Mϋller (glial) cells by the inhibitory neurotransmitter GABA
UA51682C2 (uk) Флюпіртин як активна речовина для профілактики та лікування захворювань, пов'язаних з індуктивним апоптозом лімфоцитів
DE69319346T2 (de) Bahandlung von tumoren mit neutrophischen faktoren und hemmern der zellproliferation
CN103202845B (zh) 钠通道阻滞剂和选择性5-羟色胺摄取抑制剂的药物组合物
US6350768B1 (en) Combination of riluzole and of gabapentin and its use as a medicament
White et al. 1, 9-Dideoxyforskolin does not mimick all cAMP and protein kinase a independent effects of forskolin on GABA activated ion currents in adult rat sensory neurons
Leslie Calcium channels: interactions with ethanol and other sedative-hypnotic drugs
Ito et al. Haloperidol effects on Na current in acutely isolated rat retinal ganglion cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971101